Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
European Journal of Haematology
|
March 27, 2003
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment
Gökben Baskaynak, Karl-Anton Kreuzer, Michaela Schwarz, et al.
Ejhaem
|
September 2, 2022
Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
Nina Winkelmann, Michaela Schwarz, Bert Hildebrandt, et al.
Journal of Personalized Medicine
|
July 27, 2022
Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
Ferras Alashkar, Carmen Aramayo-Singelmann, Janine Böll, et al.
Deutsche Medizinische Wochenschrift (1946)
|
April 24, 2024
[Transition in sickle cell disease - recommendations of the transition initiative sickle cell disease]
Janine Böll, Ferras Alashkar, Carmen Aramayo-Singelmann, et al.
Haematologica
|
December 18, 2009
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Theo D Kim, Seval Türkmen, Michaela Schwarz, et al.
Trials
|
August 29, 2015
Comparison of 6% hydroxyethyl starch and 5% albumin for volume replacement therapy in patients undergoing cystectomy (CHART): study protocol for a randomized controlled trial
Tobias Kammerer, Florian Klug, Michaela Schwarz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
June 25, 2014
Development of a liquid chromatography-mass spectrometry method for the determination of the neurotoxic quinolinic acid in human serum
Andreas Meinitzer, Andreas Tomaschitz, Stefan Pilz, et al.
Acta Haematologica
|
November 18, 2014
BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment
Nina Rosa Neuendorff, Michaela Schwarz, Philipp Hemmati, et al.
Acta Haematologica
|
February 8, 2014
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines
Frauke Ringel, Jaspal Kaeda, Michaela Schwarz, et al.
European Journal of Haematology
|
November 13, 2013
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
Maya Koren-Michowitz, Zehavit Buzaglo, Elena Ribakovsky, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
European Journal of Haematology
|
March 27, 2003
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment
Gökben Baskaynak, Karl-Anton Kreuzer, Michaela Schwarz, et al.
Ejhaem
|
September 2, 2022
Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
Nina Winkelmann, Michaela Schwarz, Bert Hildebrandt, et al.
Journal of Personalized Medicine
|
July 27, 2022
Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
Ferras Alashkar, Carmen Aramayo-Singelmann, Janine Böll, et al.
Deutsche Medizinische Wochenschrift (1946)
|
April 24, 2024
[Transition in sickle cell disease - recommendations of the transition initiative sickle cell disease]
Janine Böll, Ferras Alashkar, Carmen Aramayo-Singelmann, et al.
Haematologica
|
December 18, 2009
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Theo D Kim, Seval Türkmen, Michaela Schwarz, et al.
Trials
|
August 29, 2015
Comparison of 6% hydroxyethyl starch and 5% albumin for volume replacement therapy in patients undergoing cystectomy (CHART): study protocol for a randomized controlled trial
Tobias Kammerer, Florian Klug, Michaela Schwarz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
June 25, 2014
Development of a liquid chromatography-mass spectrometry method for the determination of the neurotoxic quinolinic acid in human serum
Andreas Meinitzer, Andreas Tomaschitz, Stefan Pilz, et al.
Acta Haematologica
|
November 18, 2014
BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment
Nina Rosa Neuendorff, Michaela Schwarz, Philipp Hemmati, et al.
Acta Haematologica
|
February 8, 2014
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines
Frauke Ringel, Jaspal Kaeda, Michaela Schwarz, et al.
European Journal of Haematology
|
November 13, 2013
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
Maya Koren-Michowitz, Zehavit Buzaglo, Elena Ribakovsky, et al.
Page
of 4